Funding for this research was provided by:
National Institute on Drug Abuse (UG1DA040314, 5UG1DA013034, UG1DA013720, HHSN271201400028C, UG1DA040316, UG1DA013035, U10DA013714, 5UG1DA049436-02, UG1DA015831, UG1DA020024)
Received: 10 September 2020
Accepted: 15 January 2021
First Online: 31 January 2021
Ethics approval and consent to participate
: A single independent, commercial Institutional Review Board (IRB), approved the study including providing waivers of consent and HIPAA authorization, with all sites ceding.
: Not applicable.
: Cynthia I. Campbell is supported by grants and contracts from the National Institute on Drug Abuse (UG1DA040314, R01DA047405), the Food and Drug Administration, and has support managed through her institution from a consortium of pharmaceutical companies to conduct Food and Drug Administration-mandated studies on opioids. Gavin Bart is supported by grants from NIDA and NIDDK. Robert P. Schwartz has provided consultant to Verily Life Sciences, and is the principal investigator of a NIDA-funded study that will be receiving free medication from Alkermes and Indivior. Andrew J. Saxon has royalties as Section Editor, Drug Use Disorders, UpToDate, Inc.; has travel support from Alkermes, Inc.; research support from Medicasafe, Inc.; and consulting fees from Indivior, Inc. Paige D. Wartko, Denise M. Boudreau, and Bobbi Jo H. Yarborough receive funding from a research contract through their institutions from a consortium of pharmaceutical companies (Allergan, BioDelivery Sciences, Collegium, Daiichi Sankyo, Depomed, Egalet, Endo, Janssen, Mallinckrodt, Pernix, Pfizer, Purdue, and West-Ward) to conduct Food and Drug Administration-mandated studies on opioids.